Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to recombi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Scott McComb, Mehdi Arbabi-Ghahroudi, Kevin A. Hay, Brian A. Keller, Sharlene Faulkes, Michael Rutherford, Tina Nguyen, Alex Shepherd, Cunle Wu, Anne Marcil, Annie Aubry, Greg Hussack, Devanand M. Pinto, Shannon Ryan, Shalini Raphael, Henk van Faassen, Ahmed Zafer, Qin Zhu, Susanne Maclean, Anindita Chattopadhyay, Komal Gurnani, Rénald Gilbert, Christine Gadoury, Umar Iqbal, Dorothy Fatehi, Anna Jezierski, Jez Huang, Robert A. Pon, Mhairi Sigrist, Robert A. Holt, Brad H. Nelson, Harold Atkins, Natasha Kekre, Eric Yung, John Webb, Julie S. Nielsen, Risini D. Weeratna
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-03-01
Colecção:	Molecular Therapy: Oncology
Assuntos:	MT: Regular Issue chimeric antigen receptors CD22 CAR-T nanobody single-domain antibody
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2950329924000171
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!